October 10, 2022
(press release)
–
The rate of clinical remission was 47.9 percent in patients who received combination induction therapy with guselkumab and golimumab compared with either treatment alone (31.0 percent and 20.8 percent, respectively) at 38 weeks1
The VEGA study is the first randomized controlled trial to evaluate the efficacy and safety of combination therapy with an interleukin (IL)-23p19 subunit antagonist (guselkumab) and a tumor necrosis factor-alpha (TNFα) antagonist (golimumab) in UC.3,4 Detailed results were presented today as an oral presentation (OP087) at the United European Gastroenterology (UEG) Week 2022 congress taking place in-person in
"Exploring combinations of advanced therapies is an important step in continuing to innovate for the many patients living with ulcerative colitis," said
In the VEGA study, patients with moderately to severely active UC were randomized (1:1:1) to receive combination therapy with guselkumab and golimumab, guselkumab monotherapy, or golimumab monotherapy.1 After endpoints were evaluated at week 12, patients in the monotherapy groups continued their initially assigned treatment, while patients randomized to the combination therapy group transitioned to guselkumab alone as a maintenance therapy.1 Patients remained blinded and received their respective therapies through the final efficacy assessment at week 38. Clinical remissiona,d was assessed based on the modified Mayo score (mMayo),b as well as the total Mayo score.e Symptomatic remission,f endoscopic improvement,g endoscopic remission,h histologic remission,i and composite histologic-endoscopic endpointsg,i were also assessed at week 38 in an exploratory analysis.1 Safety was evaluated through week 50 (16 weeks after the final dose of study intervention at week 34).1 Patients who received combination therapy with guselkumab and golimumab followed by maintenance treatment with guselkumab achieved clinical remissiona (mMayob) at week 38 (47.9 percent [34/71]) versus 31.0 percent (22/71) and 20.8 percent (15/72) of patients who received guselkumab or golimumab alone, respectively (nominal p=<0.05).1 Rates of clinical remissiond as defined by the total Mayo scoree at week 38 were similar to those based on the mMayo,a,b with 43.7 percent (31/71) in the combination therapy followed by guselkumab group achieving this endpoint, compared to either the guselkumab or golimumab monotherapy groups, (31.0 percent [22/71] and 22.2 percent [16/72], respectively).1 Also, patients receiving combination therapy followed by guselkumab had the following outcomes at week 38:1 Patients receiving combination therapy followed by maintenance treatment with guselkumab and patients receiving treatment only with guselkumab monotherapy achieved the same rate of symptomatic remissionf of 69 percent at week 38, which was greater than the golimumab monotherapy group of 59.7 percent.1 Rates of AEs were comparable through week 50 of the study.1 Respectively, the combination therapy followed by guselkumab, guselkumab alone, and golimumab alone groups had AE rates of 63.4, 64.8, and 76.4 percent and infection rates of 31.0, 23.9, and 31.9 percent.1 All groups had the same serious AE rates of 5.6 percent and the same serious infection rates of 2.8 percent.1 Overall, 13.1 percent of patients discontinued their treatment prior to the final dose of study intervention.1 "The 38-week VEGA data suggest the potential that guselkumab and golimumab combination therapy has in patients with moderately to severely active ulcerative colitis for whom previous conventional treatments have inadequately managed their disease or improved their well-being," said
Janssen previously announced the 12-week data of patient outcomes from the VEGA study at the 17th
Editor's Notes: a. Clinical remission (based on the mMayo) is defined as a stool frequency subscore of 0 or 1, where the stool frequency subscore has not increased from baseline, a rectal bleeding subscore of 0, and an endoscopy subscore of 0 or 1 with no friability present on endoscopy.1 b. Modified Mayo score consists of three of the four components of the full Mayo score: stool frequency, rectal bleeding, and endoscopic score. The physician global assessment score is not included.5 c.
d. Clinical remission is defined as a Mayo score ≤2, with no individual subscore >1.1 e. The total Mayo score is the sum of four subscores - stool frequency, rectal bleeding, physician's global assessment, and endoscopy findings - that are scored from normal (0) to severe (3).3 f. Symptomatic remission is defined as Mayo stool frequency subscore of 0 or 1, where the stool frequency subscore has not increased from baseline, and a rectal bleeding subscore of 0.1 g. Endoscopic improvement is defined as an endoscopy subscore of 0 or 1 with no friability present on the endoscopy.1 h. Endoscopic remission is defined as an endoscopy subscore of 0.1 i. Histologic remission is defined as absence of neutrophils from the mucosa (both lamina propria and epithelium), no crypt destruction, and no erosions, ulcerations or granulation tissue according to the Geboes grading system.1 About VEGA (NCT03662542; EudraCT 2018-001510-15) Study participants were naïve to TNFα, IL-12/23, and IL-23p19 antagonists and had to be refractory or intolerant to conventional therapy (e.g. immunosuppressants and/or corticosteroids).1 Participants were randomly assigned 1:1:1 to receive guselkumab monotherapy dosed at 200 milligrams (mg) intravenously (IV) at weeks 0, 4, and 8 followed by 100 mg every 8 weeks (q8w) subcutaneous (SC) (n=71); golimumab SC monotherapy dosed at 200 mg at week 0 followed by 100 mg SC at weeks 2, 6, and 10 followed by 100 mg every 4 weeks SC monotherapy (n=72); or a combination of 200 mg IV guselkumab plus 200 mg SC golimumab at week 0, 100 mg SC golimumab at weeks 2, 6, and 10, and 200 mg IV guselkumab at weeks 4 and 8 (n=71) followed by 100 mg guselkumab SC q8w thereafter.1 After week 12, participants in the monotherapy groups continued their initially assigned treatment, while patients randomized to the combination group transitioned to guselkumab 100 mg SC q8w as a maintenance therapy.1 The participants received their respective therapies through week 34 with final efficacy assessments at week 38.1 The primary endpoint was clinical response at week 12, defined as a decrease from baseline in the Mayo score by 30 percent or more and 3 or more points, with either a decrease in rectal bleeding subscore of 1 or more or rectal bleeding subscore of 0 or 1. The trial's major secondary endpoint was clinical remission at week 12, defined as Mayo score less than or equal to 2, with no individual subscore more than 1. No adjustments were made for multiple comparisons.2,3 Other key endpoints evaluated at week 12 were clinical remission (based on components of the mMayo score), symptomatic remission, endoscopic improvement, endoscopic remission, histologic remission, composite histologic-endoscopic endpoints, and biomarker outcomes.1 About Ulcerative Colitis About guselkumab The Janssen Pharmaceutical Companies of
IMPORTANT SAFETY INFORMATION Serious Allergic Reactions. Infections. Do not take TREMFYA® if you have had a serious allergic reaction to guselkumab or any of the ingredients in TREMFYA®. Before using TREMFYA®, tell your healthcare provider about all of your medical conditions, including if you:have any of the conditions or symptoms listed in the section "What is the most important information I should know about TREMFYA®?" Tell your healthcare provider about all the medicines you take, including prescription and over-the-counter medicines, vitamins, and herbal supplements. What are the possible side effects of TREMFYA®? TREMFYA® may cause serious side effects. See "What is the most important information I should know about TREMFYA®?" The most common side effects of\\ TREMFYA® include: upper respiratory infections, headache, injection site reactions, joint pain (arthralgia), diarrhea, stomach flu (gastroenteritis), fungal skin infections, herpes simplex infections, and bronchitis. These are not all the possible side effects of TREMFYA®. Call your doctor for medical advice about side effects. Use TREMFYA® exactly as your healthcare provider tells you to use it. Please read the fullPrescribing Information, includingMedication Guidefor TREMFYA®, and discuss any questions that you have with your doctor. You are encouraged to report negative side effects of prescription drugs to the FDA. Visitwww.fda.gov/medwatch, or call 1-800-FDA-1088. cp-82626v3 About golimumab10 IMPORTANT SAFETY INFORMATION You should not start SIMPONI® if you have any kind of infection. Tell your doctor if you are prone to or have a history of infections or have diabetes, HIV or a weak immune system. You should also tell your doctor if you are currently being treated for an infection or if you have or develop any signs of an infection such as: Your doctor will examine you for TB and perform a test to see if you have TB. If your doctor feels that you are at risk for TB, you may be treated with medicine for TB before you begin treatment with SIMPONI® and during treatment with SIMPONI®. Even if your TB test is negative, your doctor should carefully monitor you for TB infections while you are taking SIMPONI®. People who had a negative TB skin test before receiving SIMPONI® have developed active TB. Tell your doctor if you have any of the following symptoms while taking or after taking SIMPONI®: CANCER Some people treated with SIMPONI® have developed certain kinds of skin cancer. If any changes in the appearance of your skin or growths on your skin occur during or after your treatment with SIMPONI®, tell your doctor. USE WITH OTHER DRUGS HEPATITIS B INFECTION HEART FAILURE NERVOUS SYSTEM PROBLEMS IMMUNE SYSTEM PROBLEMS LIVER PROBLEMS BLOOD PROBLEMS OTHER CONSIDERATIONS TO TELL YOUR DOCTOR Tell your doctor if you are pregnant, planning to become pregnant or are breastfeeding or have a baby and were using SIMPONI® during pregnancy. Tell your baby's doctor before your baby receives any vaccine because of an increased risk of infection for up to 6 months after birth. ALLERGIC REACTIONS Common side effects of SIMPONI® include: upper respiratory tract infection, reaction at site of injection, and viral infections. PSORIASIS Please read the fullPrescribing InformationandMedication Guidefor SIMPONI® and discuss any questions you have with your doctor. You are encouraged to report negative side effects of prescription drugs to the FDA. Visitwww.fda.gov/medwatch,or call 1-800-FDA-1088. cp-51591v2 About the Janssen Pharmaceutical Companies of
Leamore at www.janssen.com. Follow us at www.twitter.com/JanssenGlobal.
Cautions Concerning Forward-Looking Statements ### References 1. Panés J, et al. Induction Combination Therapy with Guselkumab and Golimumab Followed by Guselkumab Monotherapy Maintenance: Results of the Phase 2a, Randomized, Double-blind, Proof-of-concept VEGA Study (Abstract OP087). Presented at the United European Gastroenterology (UEG) Week,
2. Sands BE, et al. Efficacy and Safety of Combination Induction Therapy with Guselkumab and Golimumab in Participants with Moderately-to-Severely Active Ulcerative Colitis: Results Through Week 12 of a Phase 2a Randomized, Double-blind, Active-controlled, Parallel-group, Multicenter, Proof-of-concept Study (Abstract OP36). Presented at the 17th
3. Clinicaltrials.gov. A Study of Efficacy and Safety of Combination Therapy With Guselkumab and Golimumab in Participants With Moderately to Severely Active Ulcerative Colitis (VEGA). Identifier: NCT03662542. Available at: https://clinicaltrials.gov/ct2/show/NCT03662542. Accessed
4.
5. Naegeli, et al. Full, Partial, and Modified Permutations of the Mayo Score: Characterizing Clinical and Patient-Reported Outcomes in Ulcerative Colitis Patients. Crohn's and Colitis 360: 2021;3;1-8. 6.
7. Crohn's &
8. Crohn's &
9. TREMFYA® Prescribing Information. Available at: https://www.janssenlabels.com/package-insert/product-monograph/prescribing-information/TREMFYA-pi.pdf. Accessed
10. SIMPONI® Prescribing Information. Available at: https://www.janssenlabels.com/package-insert/product-monograph/prescribing-information/SIMPONI-pi.pdf. Accessed
Investor Contact: Attachments Disclaimer
VEGA was a randomized, double-blind, active-controlled, parallel group, global multicenter Phase 2a proof-of-concept study evaluating the efficacy and safety of combination induction therapy with guselkumab and golimumab, followed by a transition to guselkumab monotherapy for maintenance, in patients with moderately to severely active UC as defined by a Mayo score of 6 to 12 inclusive and an endoscopy subscore of 2 or greater as determined by central read.3,4
Inflammatory bowel disease (IBD), which includes Crohn's disease and UC, affect as many as 1.6 million people in
Developed by Janssen, guselkumab (which is marketed under the brand name TREMFYA®) is the first approved fully human monoclonal antibody that selectively binds to the p19 subunit of IL-23 and inhibits its interaction with the IL-23 receptor.9 TREMFYA is approved in the
What is the most important information I should know about TREMFYA®? TREMFYA® is a prescription medicine that may cause serious side effects, including:
Stop using TREMFYA and get emergency medical help right away if you develop any of the following symptoms of a serious allergic reaction:
TREMFYAmay lower the ability of your immune system to fight infections and may increase your risk of infections. Your healthcare provider should check you for infections and tuberculosis (TB) before starting treatment with TREMFYAand may treat you for TB before you begin treatment with TREMFYA if you have a history of TB or have active TB. Your healthcare provider should watch you closely for signs and symptoms of TB during and after treatment with TREMFYA.Tell your healthcare provider right away if you have an infection or have symptoms of an infection, including:
SERIOUS INFECTIONSSIMPONI® (golimumab) is a prescription medicine. SIMPONI® can lower your ability to fight infections. There are reports of serious infections caused by bacteria, fungi, or viruses that have spread throughout the body, including tuberculosis (TB) and histoplasmosis. Some of these infections have been fatal. Your doctor will test you for TB before starting SIMPONI® and will monitor you for signs of TB during treatment. Tell your doctor if you have been in close contact with people with TB. Tell your doctor if you have been in a region (such as the
Unusual cancers have been reported in children and teenage patients taking TNF-blocker medicines. For children and adults taking TNF blockers, including SIMPONI®, the chances for getting lymphoma or other cancers may increase. Hepatosplenic T-cell lymphoma, a rare and fatal lymphoma, has occurred mostly in teenage or young adult males with Crohn's disease or ulcerative colitis who were taking other TNF blockers with azathioprine or 6-mercaptopurine. You should tell your doctor if you have had or develop lymphoma or other cancers.
Tell your doctor about all the medications you take including ORENCIA® (abatacept), KINERET® (anakinra), ACTEMRA® (tocilizumab), RITUXAN® (rituximab), or another TNF blocker, or if you are scheduled to or recently received a vaccine. People taking SIMPONI® should not receive live vaccines or treatment with a weakened bacteria (such as BCG for bladder cancer).
Reactivation of hepatitis B virus has been reported in patients who are carriers of this virus and are taking TNF-blocker medicines, such as SIMPONI®. Some of these cases have been fatal. Your doctor should do blood tests before and after you start treatment with SIMPONI®. Tell your doctor if you know or think you may be a carrier of hepatitis B virus or if you experience signs of hepatitis B infection, such as:
Heart failure can occur or get worse in people who use TNF blockers, including SIMPONI®. If you develop new or worsening heart failure with SIMPONI®, you may need treatment in a hospital, and it may result in death. Your doctor will closely monitor you if you have heart failure. Tell your doctor right away if you get new or worsening symptoms of heart failure like shortness of breath, swelling of your lower legs or feet, or sudden weight gain.
Rarely, people using TNF blockers, including SIMPONI®, can have nervous system problems such as multiple sclerosis or Guillain-Barré syndrome. Tell your doctor right away if you have symptoms like vision changes, weakness in your arms or legs, or numbness or tingling in any part of your body.
Rarely, people using TNF blockers have developed lupus-like symptoms. Tell your doctor if you have any symptoms such as a rash on your cheeks or other parts of the body, sensitivity to the sun, new joint or muscle pain, becoming very tired, chest pain or shortness of breath, swelling of the feet, ankles, and/or legs.
Serious liver problems can happen in people using TNF blockers, including SIMPONI®. Contact your doctor immediately if you develop symptoms such as feeling very tired, skin or eyes look yellow, poor appetite or vomiting, or pain on the right side of your stomach.
Low blood counts have been seen with SIMPONI®. If this occurs, your body may not make enough blood cells to help fight infections or help stop bleeding. Your doctor will check your blood counts before and during treatment. Tell your doctor if you have signs such as fever, bruising, bleeding easily, or paleness.
Tell your doctor if you are allergic to rubber or latex. The needle cover contains dry natural rubber.
Allergic reactions can happen in people who use TNF-blocker medicines, including SIMPONI®. Tell your doctor if you have any symptoms of an allergic reaction while taking SIMPONI® such as hives, swollen face, breathing trouble, or chest pain. Some reactions can be serious and life-threatening.
New or worse psoriasis symptoms may occur. Tell your doctor if you develop red scaly patches or raised bumps that are filled with pus.
At Janssen, we're creating a future where disease is a thing of the past. We're the Pharmaceutical Companies of
This press release contains "forward-looking statements" as defined in the Private Securities Litigation Reform Act of 1995 regarding guselkumab and golimumab product development. The reader is cautioned not to rely on these forward-looking statements. These statements are based on current expectations of future events. If underlying assumptions prove inaccurate or known or unknown risks or uncertainties materialize, actual results could vary materially from the expectations and projections of
Mobile: (609) 730-2922
Office: (732) 524-6164
* All content is copyrighted by Industry Intelligence, or the original respective author or source. You may not recirculate, redistrubte or publish the analysis and presentation included in the service without Industry Intelligence's prior written consent. Please review our terms of use.